274P 5-FU+Nal-IRI vs FOLFOX/XELOX as second-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after gemcitabine and nab-paclitaxel (GemNab): A propensity score-matched analysis
Title:
274P 5-FU+Nal-IRI vs FOLFOX/XELOX as second-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after gemcitabine and nab-paclitaxel (GemNab): A propensity score-matched analysis
Author:
Trovato, G. Rossini, D. Su, Y-Y. Shan, Y-S. Chiang, N-J. Chou, W-C. BagalĂ , C. Bensi, M. Niger, M. Marchesi, S. Garattini, S.K. Michelotti, A. Pretta, A. Scartozzi, M. Vivaldi, C. Bartalini, L. Procaccio, L. Chen, L-T. Tortora, G. Salvatore, L.